Year |
Citation |
Score |
2016 |
Dong M, Bi J, Liu X, Wang B, Wang J. Significant partial response of metastatic intra-abdominal and pelvic round cell liposarcoma to a small-molecule VEGFR-2 tyrosine kinase inhibitor apatinib: A case report. Medicine. 95: e4368. PMID 27495042 DOI: 10.1097/MD.0000000000004368 |
0.401 |
|
2016 |
Zhang W, Bao L, Yang S, Qian Z, Dong M, Yin L, Zhao Q, Ge K, Deng Z, Zhang J, Qi F, An Z, Yu Y, Wang Q, Wu R, et al. Tumor-selective replication herpes simplex virus-based technology significantly improves clinical detection and prognostication of viable circulating tumor cells. Oncotarget. PMID 27206795 DOI: 10.18632/Oncotarget.9465 |
0.398 |
|
2016 |
Wang Y, Cheng Q, Liu J, Dong M. Leukemia Stem Cell-Released Microvesicles Promote the Survival and Migration of Myeloid Leukemia Cells and These Effects Can Be Inhibited by MicroRNA34a Overexpression. Stem Cells International. 2016: 9313425. PMID 27127521 DOI: 10.1155/2016/9313425 |
0.353 |
|
2016 |
Sheng W, Dong M, Chen C, Li Y, Liu Q, Dong Q. Musashi2 promotes the development and progression of pancreatic cancer by down-regulating Numb protein. Oncotarget. PMID 27092875 DOI: 10.18632/oncotarget.8736 |
0.312 |
|
2016 |
Dong MH, Zhang Q, Wang YY, Zhou BS, Sun YF, Fu Q. Euphorbia fischeriana Steud inhibits malignant melanoma via modulation of the phosphoinositide-3-kinase/Akt signaling pathway. Experimental and Therapeutic Medicine. 11: 1475-1480. PMID 27073468 DOI: 10.3892/etm.2016.3061 |
0.358 |
|
2012 |
Siemann DW, Dong M, Pampo C, Shi W. Src-signaling interference impairs the dissemination of blood-borne tumor cells. Cell and Tissue Research. 349: 541-50. PMID 22526632 DOI: 10.1007/S00441-012-1415-7 |
0.49 |
|
2010 |
Dong M, Rice L, Lepler S, Pampo C, Siemann DW. Impact of the Src inhibitor saracatinib on the metastatic phenotype of a fibrosarcoma (KHT) tumor model. Anticancer Research. 30: 4405-13. PMID 21115886 |
0.538 |
|
2009 |
Siemann DW, Dong M. Abstract B107: Targeting metastatic tumor cell functions by Src signaling interference using the small molecule Src inhibitor, saracatinib (AZD0530) Molecular Cancer Therapeutics. 8. DOI: 10.1158/1535-7163.Targ-09-B107 |
0.569 |
|
Show low-probability matches. |